Endogenous testosterone levels and cardiovascular disease in healthy men

Heart

Volumn 97, Issue 11, 2011, Pages 867-869

  Channer, Kevin S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ANGINA PECTORIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFECT; EDITORIAL; HEART FAILURE; HORMONE ACTION; HUMAN; HYPOGONADISM; ISCHEMIC HEART DISEASE; MORTALITY; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE SYNTHESIS;

CARDIOVASCULAR DISEASES; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; TESTOSTERONE;

EID: 79955901469     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.217414     Document Type: Editorial

References (25)

1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13. (Pubitemid 28502636)
2. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-31. (Pubitemid 32207487)
3. Makhsida N, Shah J, Yan G, et al. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005;174:827-34. (Pubitemid 41140604)
4. Corona G, Mannucci E, Schilman C, et al. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol 2006;50:595-604. (Pubitemid 44189051)
5. Kupelian V, Page ST, Araujo AB, et al. Low sexhormone binding globulin total testosterone and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006;91:843-50. (Pubitemid 43357748)
6. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56. (Pubitemid 46630983)
7. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localised prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516-24. (Pubitemid 351767235)
8. English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000;21:890-4. (Pubitemid 30307417)
9. Makinen J, Jarvisalo MJ, Pollanen P, et al. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 2005;45:1603-8. (Pubitemid 40704493)
10. Muller M, van den Beld AW, Bots ML, et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004;109:2074-9. (Pubitemid 38620214)
11. Hak AE, Witteman JC, de Jong FH, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002;87:3632-9. (Pubitemid 34879505)
12. Nettleship JE, Jones TH, Channer KS, et al. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation 2007;116:2427-34. (Pubitemid 350145077)
13. Ruige JB, Mahmoud AM, de Bacquer D, et al. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011;97:870-5.
14. Haring B, Voltzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010;31:1491-501.
15. Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary artery disease. Heart 2010;96:1821-5.
16. English KM, Steed RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. Circulation 2000;102:1906-11.
17. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004;90:871-6. (Pubitemid 39005930)
18. Mathur A, Malkin C, Saeed B, et al. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol 2009;161:443-9.
19. Scragg JL, Jones RD, Channer KS, et al. Testosterone is a potent inhibitor of L-type Ca(2+) channels. Biochem Biophys Res Commun 2004;318:503-6.
20. Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003;24:909-15. (Pubitemid 36559984)
21. Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure; prevalence and detrimental impact on survival. Circulation 2006;114:1829-37. (Pubitemid 44673358)
22. Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double blind randomised placebo controlled trial. Eur Heart J 2006;27:57-64. (Pubitemid 41785933)
23. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity skeletal muscle performance, insulin resistance and baro-reflex sensitivity in elderly patients with chronic heart failure. J Am Coll Cardiol 2009;54:919-27.
24. Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906. (Pubitemid 43997730)
25. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109-22.